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In addition to the ability to bind the retroviral capsid protein, the retroviral restriction factors Fv1, Trim5α and Trim5–CypA share the common
property of containing sequences that promote self-association. Otherwise Fv1 and Trim5α appear unrelated. Mutational analyses showed that
restriction was invariably lost when changes designed to disrupt the sequences responsible for multimerization were introduced. A novel
restriction protein could be obtained by substituting sequences from the self-associating domain of Fv1 for the Trim5 sequences in Trim5–CypA.
Similarly, a fusion protein containing cyclophilin A joined to arfaptin2, a protein known to form extended dimers, was also shown to restrict HIV-
1. Hence, multimerization of a capsid-binding domain could be the common minimum design feature for capsid-dependent retroviral restriction
factors. However, not all domains that promote multimerization can substitute for the N-terminal domains of Fv1 and Trim5α. Moreover, only
CypA can provide a capsid-binding site with different N-terminal domains. It is suggested that the spatial relationship between the multiple target
binding sites may be important for restriction.
© 2007 Elsevier Inc. All rights reserved.Keywords: Restriction; Multimerization; Fv1; Arfaptin2; Cyclophilin AIntroduction
Retroviruses are restricted by a number of cellular factors.
Some of these act during the early phase of the lifecycle and
block the virus in a capsid (CA)-dependent manner (Stoye,
2002). The prototypic restriction factor Fv1 was first described
in the early 1970's as a genetic locus in mice that prevents
infection by certain strains of murine leukemia virus (MLV)
(Lilly, 1970). There are two major alleles of Fv1: Fv1n restricts
the B-tropic MLV while Fv1b restricts the N-tropic strain
(Hartley et al., 1970). A single amino acid change at residue 110
in CA can alter the susceptibility to restriction, suggesting a
direct interaction between virus CA and restriction factor
(Kozak and Chakraborti, 1996). Fv1 has been cloned and is
related to the Gag gene of an endogenous retrovirus, HERV-L
(Best et al., 1996).
More recently, restriction of N-tropic MLV has also been
reported in non-murine cells (Towers et al., 2000). In addition,
infection by HIV-1 is blocked in certain primate cells in a⁎ Corresponding author. Fax: +44 208/906 4477.
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doi:10.1016/j.virol.2007.04.005similar way (Besnier et al., 2002; Cowan et al., 2002). The
primate restriction factor is Trim5α (Stremlau et al., 2004), a
cellular protein that bears no apparent similarity to Fv1. Instead,
it belongs to a large family of Trim proteins containing the
tripartite motifs RING, B-Box and Coiled coil (RBCC)
(Reymond et al., 2001). In addition to the RBCC, Trim5α
also possesses a C-terminal B30.2 domain. Studies of a series of
chimeric proteins made between the human Trim5α, which
does not restrict HIV-1 well, and rhesus Trim5α, which does,
have revealed that the specificity determinants of restriction lie
in the B30.2 domain (Perez-Caballero et al., 2005; Stremlau et
al., 2005; Yap et al., 2005). Indeed, the residues in this domain
that influenced restriction were found to be under positive
selection, suggesting that the gene might have evolved to
protect against retroviral infection (Sawyer et al., 2005).
In owl monkeys, the B30.2 domain of Trim5α has been
replaced with cyclophilin A (CypA) through a retrotransposi-
tional insertion of a CypA cDNA between exons 7 and 8 of the
Trim5 locus (Nisole et al., 2004; Sayah et al., 2004). The
resulting fusion protein restricts HIV-1 in a CypA-dependent
manner; a non-binding mutant of CA, G89V, is not restricted. In
addition, restriction can also be abolished by treatment with
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(Luban et al., 1993). This suggested that in Trim5CypA, CypA
had replaced the function of the B30.2 domain in recognizing
and binding HIV-1 CA. The RBCC of Trim5CypA can also be
replaced with the RBCC from other members of the Trim
family, in particular, Trim1, Trim18 and Trim19 (Li et al.,
2006a; Yap et al., 2006; Zhang et al., 2006). These proteins do
not restrict HIV-1 but their CypA derivatives do so in a manner
that is dependent on the ability to recognize the CypA binding
loop of CA. This result suggested that the RBCC of other Trim
family members can provide any function required for
restriction. To examine the role(s) of the RBCC domain we
have now performed an analysis of the function of the N-
terminal domain and Trim5α in retrovirus restriction and used
the information obtained to design two artificial restriction
factors.
Results
The Trim5α coiled coil motif is essential for restriction
We have previously found that the B30.2 domain of Trim5α
could be replaced by CypA for HIV-1 restriction (Yap et al.,
2005). In addition, the RBCC domain of other Trim proteins is
interchangeable with that of Trim5CypA in blocking HIV-1
(Yap et al., 2006; Zhang et al., 2006). These results suggested
that the RBCC and B30.2 domains of Trim5α could function
independently of each other. The B30.2 domain has been shown
to be involved in specificity determination (Nakayama et al.,
2005; Sawyer et al., 2005; Stremlau et al., 2005; Yap et al.,
2005) and is likely to bind viral CA protein (Li et al., 2006b;
Stremlau et al., 2006). However, the precise functions of the
RBCC domain remain to be elucidated. Hence we set out to
characterize the role(s) played by the RBCC in retroviral
restriction. Point mutations that disrupted either the RING or B-
BOX motifs were introduced in rhesus (rh) Trim5α and
rhTrim5CypA (rhT5C), which contained the RBCC from
rhTrim5α fused to the CypA domain of owl monkey
Trim5CypA. This was to ensure that identical RBCCs were
being compared, one in the context of the B30.2 domain and the
other in fusion with CypA. The results are shown in Fig. 1A.
Disrupting the RING motif of rhTrim5α (rhTrim5α C15,18A)
resulted in a significant decrease in restriction of HIV-1 coupled
with complete loss of N-MLV restriction. A similar but less
dramatic reduction was also seen with the mutation of the
rhT5C RING motif (rhT5C C15,18A). Mutational disruption of
the rhTrim5α B-Box (rhTrim5α C97A,H100A) led to the
abolition of restriction activity, as reported previously (Javan-
bakht et al., 2005). Surprisingly, perturbation of the B-box did
not seem to abolish the ability of rhT5C (rhT5C C97A,H100A)
to restrict HIV-1. This suggested that the same RBCC might
have different effects on restriction when combined with
different binding domains.
Next, individual motifs in either rhTrim5α or rhT5C were
deleted. Interestingly, deletion of the RING motif had no effect
on the extent of restriction of HIV-1 by either rhTrim5α or
rhT5C (Fig. 1B). By contrast, deletion of the RING motif led tothe loss of restriction of N-MLV by rhTrim5α. A possible
explanation for the discrepancy between the RING deletion and
point mutants (C15,18A) could be that the latter contains
regions of unordered structure due to the loss of zinc co-
ordination, which could block restriction by steric hindrance.
This misfolded structure would be completely removed by
deletion of the RING, thus restoring restriction of HIV-1.
Restriction of HIV-1 in the absence of the RING also suggested
that the ubiquitin ligase activity of the RBCC is dispensable for
restriction by rhT5C. Removal of the B-Box resulted in a loss of
restriction of both HIV-1 and N-MLV by rhTrim5α. However,
loss of the B-Box did not abolish HIV-1 restriction by rhT5C.
This confirmed our previous result with the point mutant C97A,
H100A. Deletion of the coiled coil motif, however, led to the
loss of all retroviral restriction by rhTrim5α as well as rhT5C.
Hence, the coiled coil motif seems to be the only motif whose
presence is absolutely required by both rhTrim5α as well as
rhT5C to maintain activity. All mutated proteins were expressed
at levels similar to, or greater than, wild type, ruling out the
possibility that the loss of restriction was due to destabilization
of the altered proteins (Fig. 1C).
Since the RING and B-Box were independently dispensable
for restriction by rhT5C, it seemed likely that the motifs could
be removed without affecting restriction. Surprisingly, however,
restriction was abolished in the double RING/B-Box deletion of
rhTrim5α and markedly reduced in the double RING/B-Box
deletion mutant rhT5CdelRINGBOX, although some residual
restriction of HIV-1 was evident (Fig. 1B). Taken together, these
results suggested that the RING and B-Box could be supporting
the role of the coiled coil as either one could be removed but the
absence of both led to a major reduction of restriction efficiency.
Nevertheless, these results suggest that the minimal require-
ments for a factor with restriction activity are the presence of
multimerization and binding domains.
The N-terminal domain of Fv1 can replace the RBCC in
Trim5CypA restriction of HIV-1
We next set out to test the idea that it might be possible to
generate an artificial restriction factor by combining any
multimerization domain with a CA-binding domain. These
initial attempts were unsuccessful. Hybrid molecules generated
by fusing glutathione-S-transferase (dimer (Vargo et al., 2004)),
Rad50 (dimer (Hopfner et al., 2002)) or α-tubulin (higher
multimer (Nogales and Wang, 2006)) to CypA did not restrict
HIV (Fig. 2).
Postulating that the separation of the CA binding
domains might play an important role in determining the
restriction potential of the hybrid molecule we next tested
fusions between the N-terminal domain of the Fv1 protein
and CypA. Fv1 is a gene in mice that confers resistance to
MLV (Lilly, 1970). Like Trim5α, Fv1 restriction is CA-
dependent (Kozak and Chakraborti, 1996) and saturable
(Duran-Troise et al., 1977). Functional analyses of Fv1
suggested that it consists of 2 domains separated by a
flexible linker (Bishop et al., 2001). Initial studies indicated
that the N-terminal domain is involved in localization while
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Fig. 2. Functional analyses of GST, Rad50 or α-tubulin fusions to CypA. The structure of the fusion proteins is shown on the left with numbers indicating the start and
end amino acids of the CypA fusion partner. Restriction data, measured as described for Fig. 1 are shown on the right.
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multimerization signals (Yap and Stoye, 2003). More recent
studies have shown that the N-terminal domain of Fv1 is
also capable of multimerization, adopting an extended dimer
conformation when expressed in Escherichia coli or
baculovirus vectors (Bishop et al., 2006). In addition, the
COILS program of EMBnet predicts a coiled coil motif in
the N-terminal domain of Fv1 between residues 82 to 116
with greater than 99% probability.
To test whether the N-terminal domain of Fv1 can
replace that of Trim5, different lengths of the 5′ end of the
Fv1 gene were joined to the CypA encoding region of
OMKTrim5CypA and the resulting fusion proteins were
tested for their ability to restrict HIV-1. Cells transduced
with CypA alone did not restrict HIV-1 (Fig. 3A). By
contrast, fusion proteins that contained at least the first 158
residues of Fv1 fused to CypA were found to restrict HIV-1
but not the non-binding mutant G89V. Fv1(1–138)CypA and
Fv1(1–148)CypA, did not show restriction. However,
protein studies revealed that these constructs show little if
any stable expression (Fig. 3B). These results suggested that
the first 158 residues in Fv1 contained a function that was
performed by the RBCC of Trim proteins in HIV-1
restriction and provide compelling evidence that the N-
terminal domain of Fv1 can functionally replace the RBCC
domain in Trim5CypA-mediated HIV restriction, implying
that dimeric binding of CypA to HIV-1 can block virus
replication.
Fusion of dimer-forming Arfaptin2 to CypA results in the
restriction of HIV-1
To examine the generality of this observation we fused
CypA, to Arfaptin2, a protein that had previously been shown to
form strong dimers (Tarricone et al., 2001). Arfaptin2 mediates
cross-talk between Rac and Arf GTPases (D'Souza-Schorey etFig. 1. Functional analyses of the RBCC domain. (A) Substitution mutants. (B) Deleti
effects on the restriction of different viruses are shown on the right. Restriction assa
percentage infected Trim positive cells to percentage infected Trim negative cells. A
taken as no restriction. Values between 0.3 and 0.7 are interpreted as partial restriction
transduced with the restriction factor constructs were lysed and restriction factor exal., 1997). There have been no previous reports of any link
between this protein and the retroviral infection cycle and it
does not restrict HIV-1 (Fig. 4A). The structure of arfaptin2 has
been solved and was found to contain a BAR domain that forms
a crescent shaped dimer (Tarricone et al., 2001). The C-terminus
of each monomer resided in the middle of the crescent while the
N-terminus was unstructured. We reasoned that fusing CypA to
the C-terminus of Arfaptin2 might either disrupt the dimer
formation or hinder binding to CA. Instead, a fusion protein was
constructed by fusing the entire Arfaptin2 reading frame to the
C-terminus of CypA. Restriction assays showed that CypA–
Arfaptin2 (1–341) restricted HIV-1 but not the non-binding
mutant G89V, confirming that dimerization of a CA-binding
domain was sufficient to bring about restriction (Fig. 4A). The
structure of the first 117 residues of Arfaptin2 remains unknown
(Tarricone et al., 2001). To investigate if this region was
contributing to the restriction, 2 other constructs were made
containing different lengths of Arfaptin2. While CypA–
Arfaptin2 (60–341), which was missing half of the N-terminal
region, could still restrict HIV-1 (Fig. 4A), this ability was lost
when the first 117 residues of Arfaptin2 was removed in CypA–
Arfaptin2 (118–341), although the latter construct contained an
intact BAR domain. This suggested that a linker region between
the dimerization domain and the CA-binding domain was
important for restriction.
Arfaptin2 has been shown to associate with the trans Golgi
network (Peter et al., 2004). Since Fv1 is associated with
tubules of the trans Golgi network (Yap and Stoye, 2003), it
seemed possible that the restriction of CypA–Arfaptin2 was due
to a re-targeting of the CA-binding motif to the trans Golgi
network. To test this possibility, two double-point mutants of
CypA–Arfaptin2 were made, K226E, Q227E and R232E,
R239E. These mutants had been previously shown to abolish
localization to the trans Golgi network while retaining structural
integrity (Peter et al., 2004). Localization studies confirmed that
Arfaptin2 and CypA–Arfaptin2 localize to the trans Golgion mutants. A schematic representation of the mutation is shown on the left while
ys were performed by FACS analyses of HT1080 cells to determine the ratio of
ratio that is less than 0.3 is scored as restriction while a ratio greater than 0.7 is
. Ratios indicating restriction are boxed. (C) Analysis of protein expression. Cells
pression levels analyzed by Western blotting using an anti-Trim5α antibody.
Fig. 3. Restriction of HIV-1 by Fv1CypA fusion proteins. (A) Restriction
analyses. A schematic representation of the different lengths of Fv1CypA fusion
proteins and the mutant derivatives are shown on the left while the restriction
ratio is indicated on the right. Restriction assays were performed as described for
Fig. 1. Values indicating restriction are boxed. (B) Western blot analysis of
Fv1CypA fusion proteins with anti-Fv1.
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(not shown) mutants were evenly distributed through the
cytoplasm. The non-localizing mutants still retained the ability
to block HIV-1, suggesting that the dimerization feature of this
protein and not the localization signal was important for HIV-1
restriction.
To confirm the restriction properties of Fv1(1–158)CypA
and CypA–Arfaptin2, we introduced these genes into vectors
encoding neomycin resistance, established permanent cell
cultures by selection with G418 followed by HIV-1 titration
(Fig. 5). Fv1(1–158)CypA restricted HIV-1 almost as effi-
ciently as rhT5C, but CypA–Arfaptin2, although showing
greater than five fold inhibition was significantly less efficient.
Robust inhibition by rhT5CdeltaBOX was also confirmed in
this experiment, although this was somewhat less potent than
rhT5C. Conversely, rhTrim5αdeltaBOX appeared not to inhibit
HIV-1 infection at all giving titres slightly higher than the
negative control.
Restriction properties of Fv1CypA and CypA–Arfaptin2
To help understand the mechanism of action of Fv1CypA
and CypA–Arfaptin2, the stage of the viral life cycle that they
blocked was determined by quantifying the products ofreverse transcription and 2-LTR circles. Cells transduced with
the restriction factors were infected with equivalent amounts
of HIV-1 and total DNA was isolated 7 h or 24 h following
infection. Quantitative PCR was performed to detect products
of reverse transcription and 2-LTR circles, respectively. As
described previously, there was less reverse transcription
product detected for cells expressing OMK Trim5CypA (Yap
et al., 2006) (Fig. 6). CypA–Arfaptin2 did not seem to reduce
the amount of reverse transcription product compared to the
negative control. Fv1CypA, however, resulted in an inter-
mediate level of reverse transcription. Correspondingly, there
were fewer 2-LTR circles detected in cells expressing OMK
Trim5CypA (Fig. 6B). Fv1CypA also seemed to reduce the
number of 2-LTR circles while CypA–Arfaptin2 did not have
an effect. Taken together, these results suggested that
Fv1CypA could reduce the process of reverse transcription,
although not as efficiently as OMK Trim5CypA. However, it
did reduce the amount of 2-LTR circles, which are an
indication of nuclear translocation (Brown, 1997), at least as
well as Trim5CypA. CypA–Arfaptin2, on the other hand did
not affect either reverse transcription or nuclear entry. Hence,
the novel restriction factors blocked different stages of the
viral lifecycle, with Fv1CypA possibly acting at more than
one stage.
Analysis of the multimerization status of Fv1Cyp and
CypA–Arfaptin2 constructs
Fv1(20–200) and Arfaptin2 are dimers (Bishop et al., 2006;
Tarricone et al., 2001). Although it seemed extremely unlikely
that fusion to CypA would alter the multimerization status of
these proteins it seemed important to exclude this formal
possibility by co-precipitation and molecular weight determina-
tion experiments. In the first series of experiments HA-tagged
CypA fusions were co-transfected with a variety of untagged
Fv1 or Arfaptin2 constructs. Lysates from these cells were
precipitated with anti-HA antibody and analyzed by Western
blotting using antibodies to Fv1 or Arfaptin2 (Figs. 7A, B).
Immunoprecipitation of the untagged proteins was only seen in
the presence of HA-tagged protein implying the presence of
dimers or higher-order multimers with both Fv1(1–158)CypA
and CypA–Arfaptin2.
To examine the extent of multimerization we analyzed
purified Fv1(1–200)CypA by size exclusion chromatography
using multi-angle laser light scattering (Wen et al., 1996), a
method yielding an estimate of absolute molecular weight. The
chromatogram recorded by the differential refractometer and
that recorded from the intensity of scattered light yield co-
incident peaks (Fig. 8A) indicating uniformity of the protein
species. Molecular weight analysis gave a value of 81 kDa (Fig.
8B), exactly twice the size of the formula molecular weight for
Fv1(1–200)CypA implying that this protein is indeed a dimer.
Discussion
Functional analyses of the RBCC belonging to rhTrim5α
and rhT5C have revealed that the coiled coil motif is essential
Fig. 4. Restriction of HIV-1 by CypA–Arfaptin2. (A) Schematic representations of the fusion proteins and the mutant derivatives are shown on the left and the
restriction data indicated on the right. Restriction assays were performed as described for Fig. 1. Values representing restriction are boxed. (B) Immunofluorescence
analyses. Arfaptin2 and CypA–Arfaptin2 were detected with anti-Por1 followed by TRITC-conjugated anti-goat IgG and are shown in red. Nuclei were stained with
DAPI and shown in blue.
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the N-terminal domain of Fv1. Although there is no sequence
homology between Fv1 and Trim5α, they both restrict retro-
viruses in a CA-dependent manner. In the Trim proteins, the
coiled coil has been implicated in protein–protein interactions
(Reymond et al., 2001) and has been reported to mediate
homomultimerization leading to the formation of trimeric Trim5
(Mische et al., 2005). The importance of multimerization is
supported by the present observations that novel factors that
restrict HIV-1 can be created by fusing a binding domain,
CypA, to a multimerization domain, either from Fv1 or from the
totally unrelated Arfaptin2.
Multimerization of the restriction factor could contribute
to its antiviral activity in several ways. It could serve to
increase the avidity of the factor for CA through promoting
the attachment of several binding domains simultaneously in
a manner analogous to the binding of sialic acid residues by
influenza hemagglutinin (Skehel and Wiley, 2000). Thus,
monomeric CypA binds HIV-1 CA relatively weakly with a
dissociation constant in the low μM range (Howard et al.,
2003; Yoo et al., 1997). However, simultaneous binding of
two or three joined CypA domains to a lattice of CA targets
would give rise to an apparent Kd corresponding to
essentially irreversible binding. The failure to detect directbinding of Fv1 or Trim5α to unpolymerized CA from MLV
or HIV-1 might reflect a monomer binding affinity say in
the high μM or low mM range. Such binding might have
limited consequences unless multiple interactions took place.
In such a way tight binding might occur, securely anchoring
biochemical signals, for example specifying interactions with
the proteasome (Wu et al., 2006), on the restriction factor to
its target, even when the restriction factor is present at very
low concentrations within the cell.
Multimerization could also have more direct effects on
restriction by cross-linking several subunits of CA on the
surface of the viral core very soon after entry into the cyto-
plasm. The binding of several CA subunits might interfere with
the controlled disassembly (Forshey et al., 2002) that is required
for reverse transcription resulting in the absence of early reverse
transcriptase products. Alternatively, the cross-linked CA sub-
units might prevent a reorganization of the viral core, a process
that could be required to allow formation of a more compact
structure that could pass through the nuclear pore. This could
account for the reduction in the 2-LTR circle formation,
which is taken as an indication of nuclear entry. Finally,
cross-linking of the CA molecules that remain associated
with the translocated pre-integration complex could interfere
with the steps that are involved in integration. This could
Fig. 5. Restriction in stable cell lines expressing restriction factors. (A) Restriction analysis. Human HT1080 cells were transduced with vectors containing the
neomycin resistance gene and either RhT5C, Fv1(1–158)CypA, CypA–Arfaptin2(1–341), RhT5CdeltaBOX or RhTrim5deltaBOX (all HA-tagged). The cells were
selected in media containing G418 (1 mg/ml) for 2 weeks before infecting with increasing infectious units of HIV-1 carrying the GFP marker. The percentage of cells
transduced was determined by FACS analysis and plotted against infectious units of HIV-1. Essentially identical data were obtained with untagged restriction factors.
(B) Restriction factor expression. The selected cells were seeded in 6-cm dishes, grown to confluence and lysed with 500 μl of 1% NP40 lysis buffer. Aliquots (25 μg
total protein) were used forWestern blot analysis using anti-HA followed by anti-rabbit HRP. Lanes 1: RhT5CHA; 2: RhTrim5deltaBOXHA; 3: RhCypAdeltaBOXHA;
4: Fv1(1–158)CypHA; 5: CypArfaptin2; 6: Non-transduced cells.
308 M.W. Yap et al. / Virology 365 (2007) 302–314account for the very late block by restriction factors such as
CypA–Arfaptin.
Despite having no homology at the sequence level, Fv1
and Trim5α seem to share a similar structural organization.
Both have a multimerization domain that is followed by a
binding domain. Some of these domains are interchangeable
like the RBCC and Fv1 coiled coil in the case of fusions to
CypA. On the other hand, we have observed that fusion
proteins containing the N-terminal domain of Fv1 fused to the
B30.2 domain of rhTrim5α and the RBCC of rhTrim5α fused
to the C-terminal domain of Fv1 had no restriction activity
(data not shown). However, novel restriction factors like
CypA–Arfaptin2 can be constructed based on this organiza-
tion. In the case of CypA–Arfaptin2, the binding domain
precedes the multimerization domain at the sequence level.
Thus, structurally, the organization would still be analogous
to Trim5α and Fv1 with binding domains linked by an
extended multimerization domain. However, the nature of themultimerization domain can differ; while the Trim5 RBCC
domain forms a trimer (Mische et al., 2005), the N-terminal
domain of Fv1 (Bishop et al., 2006) and the Arfaptin 2
(Tarricone et al., 2001) molecule are dimers. Hence, while
trimerization as seen with Trim5α and Trim5CypA is not an
absolute requirement for restriction, the ability to multimerize
plays an essential role. It would be interesting to study the
effects of different states of multimerization on the stage of
block in the viral life cycle. A trimer, for example, might be
more efficient at holding the core together and preventing
disassembly, thereby blocking early while a dimer might not
hinder disassembly but could remain bound to the CA on the
disassembled core to affect steps in trafficking or integration.
Multimerization is clearly an integral part of retroviral
restriction (Javanbakht et al., 2005; Perez-Caballero et al.,
2005). However, the ability to multimerize does not seem to be
sufficient for retroviral restriction. This is highlighted by the
fact that not all domains that promote multimerization could
Fig. 6. Staging of block in the viral life-cycle by Fv1(1–158)CypA and CypA–Arfaptin2(1–341). (A) Quantification of products of early reverse transcription. TE671
Cells expressing restriction factors were infected with HIV-1 and total DNAwas harvested 7 h post-infection. Quantitative PCR was performed using 150 ng of total
DNA. (B) Quantification of 2-LTR circles. Cells expressing restriction factors were infected with HIV-1 and total DNAwas harvested 24 h post-infection. Quantitative
PCR was performed using 500 ng of total DNA.
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CypA to GST, Rad50 or α-tubulin did not result in restriction of
HIV-1. It is not clear what features these proteins lack that are
common to Fv1 and Arfaptin2. Fv1 is a restriction factor and
might conceivably possess some as yet unidentified motif
necessary for restriction but it seems unlikely that this feature
would be shared with Arfaptin2. Rather, It is tempting to
suggest that the dimensions of the multimerization domain may
play an important role. Arfaptin2, which is able to provide the
multimerization function to restrict, contains an extended Bar
domain which separates the two CypA domains by about 140 Å
(Tarricone et al., 2001). The N-terminal domain of Fv1
containing the coiled coil can also provide this function.
Although the predicted coiled coil was only between residues
82 and 116, at least the first 158 residues of Fv1 were required
for restriction. This region of Fv1 was recently reported to form
an extended dimer resembling the arfaptin2 dimer (Bishop et al.,
2006). Hence, it is possible that there is a minimal length
requirement for the multimerization domain. In addition, linker
regions between the multimerization and binding domains
could also be important, as observed in Fv1 and CypA–Arfaptin2. Indeed, recent studies have shown that the linker
region between the coiled coil and B30.2 domain is also
required for trimerization (Javanbakht et al., 2006), indicating
the possibility of the interaction domain extending beyond the
predicted coiled coil. In the context of the hexameric
arrangement of CA on the surface of the core (Li et al., 2000;
Mortuza et al., 2004), the distance between adjacent CA
molecules is likely to be too small to allow binding of an
extended multimer of restriction factor to adjacent CA
molecules. Perhaps restriction requires binding to CA mole-
cules positioned in different hexameric rings of the core.
The precise roles of the RING and B-Box motifs in
restriction remain to be elucidated. Previous studies have
shown that deletion of either region leads to a significant loss of
restriction activity suggesting that both regions may supply
some effector functions required for activity (Diaz-Griffero et
al., 2006; Javanbakht et al., 2005; Perez-Caballero et al., 2005;
Stremlau et al., 2004). However, some of our data, most
strikingly with rhT5CdeltaBOX, are inconsistent with this
interpretation. Possibly very subtle differences in the construc-
tion of the different expression constructs are responsible.
Fig. 7. Co-immunoprecipitations using HA tagged proteins. (A) Immunopre-
cipitation of GFP-tagged Fv1 with Fv1CypAHA. Human 293T cells were
transfected with 10 μg of plasmids expressing the factors indicated on the top of
the figure. In cases where only one factor was introduced, 10 μg of the empty
vector pLgatewayIRESYFP was used to make the total DNA transfected up to
20 μg. The cells were harvested for immunoprecipitation with anti-HA agarose
after which 5 μl of the input material and 20 μl of the immunoprecipitate were
used in Western blot analyses using anti-Fv1. (B) Immunoprecipitation of
arfaptin2 with CypArfaptinHA. Human 293T cells were transfected with 10 μg
of plasmids expressing the factors indicated on the top of the figure. In cases
where only one factor was introduced, 10 μg of the empty vector
pLgatewayIRESYFP was used to make the total DNA transfected up to
20 μg. The cells were harvested for immunoprecipitation with anti-HA agarose
after which 5 μl of the input material and 20 μl of the immunoprecipitate were
used in Western blot analyses using anti-Arfaptin.
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ences in expression level. It is noteworthy that essentially all
mutational studies so far reported in this area have been
performed using transduced or transfected constructs. This
results in very much higher levels of protein expression than for
naturally expressed Trim5α, T5C or Fv1. Distinguishing effects
resulting from over-expression from those caused by the
introduced mutations remains a major challenge for all who
work in this field. Nevertheless, it is clear that the RING and B-
Box are entirely dispensable in the contexts of Fv1(1–158)CypA and CypA–Arfaptin2 (1–341) as expressed here. Thus if
an effector function is absolutely required for restriction, it must
be supplied by some other protein motif. Confounding, or
perhaps suggesting a solution to, this problem are observations
that different restriction factors can act at different stages in the
viral life cycle, perhaps acting in differentways (Yap et al., 2006).
Indeed, individual factors, for example Trim5α, Trim5CypA
and, possibly, Fv1(1–158)CypA (see Fig. 6) can show effects at
different stages (Anderson et al., 2006; Wu et al., 2006).
Untangling the different mechanisms of restriction remains a
formidable task.
Materials and methods
Cell lines and virus production
All cells were maintained in Dulbecco's modified Eagle's
media containing 10% fetal calf serum and 1% penicillin/
streptomycin. Viruses were produced by transient transfection
of 293T cells as previously described (Soneoka et al., 1995). All
viruses were pseudotyped with VSVG expressed from the
plasmid pCZVSVG (Bock et al., 2000). The EGFP marker was
expressed from vectors pCSGW (Bainbridge et al., 2001) and
pLNCG (Yap et al., 2004) for HIV-1 and MLV respectively.
HIV-1 Gag–pol was produced from either p8.91 (wild type)
(Zufferey et al., 1997) or pG89V (cyclophilin A non-binding
mutant) (Yap et al., 2004). All restriction genes were expressed
from derivatives of pLGatewayIEYFP (Yap et al., 2004) or
pLGatewaySN that was delivered using the Moloney gag–pol
from pHIT60.
Plasmid constructs
The retroviral vector, pLGatewaySN was constructed by
inserting the Gateway Reading Frame A (Invitrogen) fragment
into the HpaI site of pLXSN.
RBCC point mutants of rhTrim5 and rhT5C were made by
site-directed mutagenesis of plasmids pLrhTrim5IEYFP and
pLrhT5CIEYFP as described previously (Yap et al., 2005).
Deletion mutants were constructed by overlapping, two-stage
PCR using the primers listed in Table 1. The gene to be deleted
was amplified in 2 fragments: the first before the deleted
section, with primer pair DeltaRINGRev, DeltaBoxRev or
DeltaCoilRev and Trim5F, and the second after the deletion
with primer pair Trim5Rev or CypARev and DeltaRINGF,
DeltaBoxF or DeltaCoilF. The 2 fragments were then joined by
amplifying with Trim5F and Trim5Rev or CypARev. The
Fv1CypA and CypA–Arfaptin2 fusions were also made using
overlapping PCR. Different lengths from the N-terminus of Fv1
were amplified with the forward primer Fv1F and reverse
primers FCrev1, FCrev2, FCrev3, FCrev4, FCrev5, FCrev6,
FCrev7 and FCrev8, while the CypA domain of OMKT5C was
amplified with forward primers FCF1, FCF2, FCF3, FCF4,
FCF5, FCF6, FCF7, FCF8 and reverse primer CypARev. The
fragments were gel-purified and used in a second PCR reaction
with primer-pairs Fv1F and CypARev to generate the Fv1CypA
fusions. Similarly, the CypA fragment from amplification of
Fig. 8. Determination of the solution molecular weight of Fv1(1–200)CypA. (A) Elution profile produced by application of 200 μg of Nickel–chelate affinity purified
Fv1(1–200)CypA to a Superdex 200 10/300 GL column. The filled line is the chromatogram recorded by differential refractometer (right side axis) and the dashed line
is the chromatogram recorded from the intensity of scattered light at 90° (left side axis). (B) Analysis of solution molecular weight of Fv1(1–200)CypA. The filled line
is the recorded differential refractive index (right side axis) and the points are individual measurements of the weight-averaged molecular weight determined at 1-s
intervals (left side axis).
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CypArfRev1, CypArfRev2 or CypArfRev3 was joined to the
product from the amplification of pGEXArfaptin2 with forward
primers CypArfF1, CypArfF2, CypArfF3 and reverse primer
Arfaptin2Rev with primers CypAF and Arfaptin2Rev to
produce the CypA–Arfaptin2 fusions. Arfaptin2 was amplified
from pGEXArfaptin2 with primer pairs Arfaptin2F and
Arfaptin2Rev. All final PCR products were cloned into
TopoDENTR vector (Invitrogen) before insertion into pLGate-
way or IYFP pLGatewaySN using LR clonase (Invitrogen) and
sequencing. Various constructs were retrofitted with a HA tag by
PCR using the original forward primer plus HACypARev
(CTAAGCGTAATCTGGAACATCGTATGGGTATTCGAGT-
TGTCCACAGTCAGCAATGG) or HAarfRev (CTAAGCG-
TAATCTGGAACATCGTATGGGTACTGCTCCTCTAGC-
CAGGAGGGTTTC), before cloning into the TopoDENTR and
reinsertion into the Gateway vector. Hybrid molecules fusing
GST, Rad50 or α-tubulin to CypA were generated similarly
(details available on request).
Restriction assays
Restriction assays were routinely performed using FACS
analysis of HT1080 cells to determine the ratio of the
percentage of restriction factor expressing cells that were
infected to that of non-expressing cells by two-color FACS
analysis as previously described (Bock et al., 2000; Yap et al.,
2004). A ratio of less than 0.3 was taken as strong restriction
while a ratio that was more than 0.7 was taken as no restriction.
Ratios between 0.3 and 0.7 were taken to indicate partial
restriction. Alternatively, HT1080 cells were transduced with
restriction genes cloned in pLGatewaySN. The cells were
selected on G418 (1 mg/ml) for 2 weeks before seeding in 12-well plates at a density of 5×104 cells per well. The cells were
then challenged with different quantities of HIV-1 carrying the
GFP marker and the percentage of infected cells assessed by
FACS 3 days post-infection.
Western blot analyses
Cells were seeded in 12 well plates to a density of 5×104
cells per well 24 h pre-transduction. The cells were
transduced with retroviral vectors carrying the restriction
gene so the 70% of the cells were transduced as determined
by FACS analyses of the EYFP marker. The transduced cells
were plated in 6 cm dishes and grown to confluency before
lysing with buffer containing 1% NP40. Bradford assays
were performed to determine the total protein concentration
of the cell lysates and 25 μg of total protein was loaded in
each lane of a SDS–polyacrylamide gel. The separated bands
were transferred onto a PVDF membrane which was blocked
overnight in PBS containing 0.1% Tween and 5% milk.
Primary and secondary antibody binding were performed in
PBS containing 0.1% Tween and 5% milk with four washes
of 5 min each in PBS containing 0.1% Tween and 0.5%
milk. Goat anti-Trim5α (AbCam) and Rabbit anti-Fv1
(Bishop et al., 2001) were used at dilutions of 1:1000,
while HRP–anti-goat (Vector laboratories) and HRP–anti-
rabbit (Pierce) were used at dilutions of 1:1000 and 1:5000,
respectively. Detection was performed using the ECL reagent
from Amersham.
Co-immunoprecipitation
Fv1(1–158)CypAHA or CypArfaptinHAwere co-expressed
with untagged proteins in 293Tcells, which were seeded in 6 cm
Table 1
Primers used to construct the Fv1CypA and CypA–Arfaptin2 fusion proteins
and deletion mutants of rhTrim5/rhT5C
Trim5F CAC CAT GGC TTC TGG AAT CCT GG
DeltaRINGF GGA GGT GAC CCG GAT CAG TTA CCA GCC TGA G
DeltaRINGRev AAC TGATCCGGG TCACCT CCT CCT TTA CAT TAA C
DeltaBoxF GGT TGATCA CAC TTT CCT CAT GGA GGA GGT TG
DeltaBoxRev TGA GGA AAG TGT GAT CAA CCT TCT GTC CCT C
DeltaCoilF CCA CAC TTT CAT CTC AGA ACT GGA GCATCG G
DeltaCoilRev GTT CTG AGATGA AAG TGT GGT GAC CAC GGT G
Trim5Rev TCA AGA GCT TGG TGA GCA CAG
Fv1F CAC CAT GAATTT CCC ACG TGC GCT TG
FCRev1 CGG CGG CGT CTT TCC GGG CAG GCT GAC ACATG
FCF1 TGC CCG GAA AGA CGC CGC CGC CTG GGA CCT TG
FCRev2 CGG CGG CGT CGG CCA AGA CAG TGG GCA ACT C
FCF2 TGT CTT GGC CGA CGC CGC CGC CTG GGA CCT TG
FCRev3 CGG CGG CGT CAG TCT CCC CCA GGA CAC ACT TAG
FCF3 GGG GGA GAC TGA CGC CGC CGC CTG GGA CCT TG
FCRev4 CGG CGG CGT CTT CAG TCT GTT TTT CCC CAA C
FCF4 ACA GAC TGA AGA CGC CGC CGC CTG GGA CCT TG
FCRev5 CGG CGG CGT CTT GCA CAT CAG CTA ACC TCA C
FCF5 TGATGT GCA AGA CGC CGC CGC CTG GGA CCT TG
FCRev6 CGG CGG CGT CAATCA GTG CCC TCA CCT TAT C
FCF6 GGC ACT GAT TGA CGC CGC CGC CTG GGA CCT TG
FCRev7 CGG CGG CGT CAT CCC AGG TTA CCG GAT CCC
FCF7 AAC CTG GGATGA CGC CGC CGC CTG GGA CCT TG
FCRev8 CGG CGG CGT CTT CAG AAT CTA TGT CCT CCC AC
FCF8 AGATTC TGA AGA CGC CGC CGC CTG GGA CCT TG
CypARev GCG GCC GCC TCG AGT TAT TCG AGT TGT CCA CAG
TC
CypAF CAC CAT GGA CGC CGC CGC CTG GGA CCT TG
CypArfRev1 TCC CGT CCG TAA GTT GTC CAC AGT CAG CAATG
CypArfF1 TGG ACA ACT TAC GGA CGG GAT CCT AGG GAA G
CypArfRev2 TGA GTC CAT CAA GTT GTC CAC AGT CAG CAATG
CypArfF2 TGG ACA ACT TGATGG ACT CAT CCC CAC AGG G
CypArfRev3 TCC GTG AGC CAA GTT GTC CAC AGT CAG CAATG
CypArfF3 TGG ACA ACT TGG CTC ACG GAC TGT GGA CCT GG
Arfaptin2Rev TCA CTG CTC CTC TAG CCA GG
Arfaptin2F CAC CAT GAC GGA CGG GAT CCT AGG G
312 M.W. Yap et al. / Virology 365 (2007) 302–314dishes at a density of 2×106 cells per dish 24 h before
transfection. The cells were transfected with 10 μg of each
plasmid. In dishes where only one factor was transfected, the
empty vector pLgatewayIRESYFP was used to make the total
amount of DNA up to 20 μg. Cell lysates were harvested 48 h
post-transfection and used immediately for immunoprecipita-
tion. Immunoprecipitation was performed using the anti-HA
immunoprecipitation kit from Sigma. The transfected cells were
lysed with 550 μl Cell Lytic M Cell lysis reagent containing
complete protease inhibitor cocktail from Roche at 4 °C for
45 min. The lysates were then cleared by centrifugation at
12000×g for 15 min at 4 °C and 50 μl was saved for analysis of
the input material while the rest was transferred to spin columns
together with 10 μl of anti-HA agarose and 90 μl of 1× IP buffer.
The reaction was allowed to proceed at 4°C for 4 h with mixing
before washing 6 times with 700 μl 1× IP buffer each. A final
wash with 0.1× IP buffer was performed before eluting with
60 μl of 1×SDS PAGE loading buffer at 95 °C for 10 min. The
immunoprecipitates (20 μl) and input material (5 μl) were
analyzed in Western blots using anti-Fv1 (1:3000 dilution) or
anti-arfaptin2 (1:2000 dilution) followed by anti-rabbit–HRP
(1:10000) or anti-goat–HRP (1:10000), respectively.Immunofluorescence analyses
Cells were plated in 12-well plates at a density of 5×104 24 h
prior to transduction with retroviral vectors carrying the different
restriction genes. The transduced cells were seeded onto
coverslips in 12-well plates 2 days post-transduction and
allowed to adhere for 24 h before fixing for 15 min with 4%
paraformaldehyde in PBS. This was followed by permeabilizing
with 0.2% Triton X in PBS for 15 min and one wash with PBS.
Blocking in 1% BSA in PBS was performed for 20 min before
binding of primary antibody in PBS containing 1% BSA for 1 h.
Anti-Por1 (Santa Cruz) was used at a dilution of 1:200. The cells
were washed 3 times in PBS containing 1% BSA for 5 min each
before proceeding to secondary antibody binding for 1 h with
Texas Red-conjugated anti-rabbit antisera (Santa Cruz) at a
dilution of 1:400. Coverslips were washed 3 times with PBS
before mounting on a slide. Microscopy was performed using a
using a Deltavison Olympus IX70 inverted microscope through
a 100× objective lens with Softworx image acquisition software.
Quantitative PCR
Virus stocks were treated with RNase-free DNase (Promega)
at 10 units/ml for 1 h before infecting TE671 cells expressing
different restriction factors. Total cellular DNA was extracted
using the DNeasy kit from Qiagen at 7 and 24 h post-infection
for detection of reverse transcription products and 2-LTR
circles, respectively. The extracted DNA was quantified with a
spectrophotometer and 150 ng was used per reaction for
detecting RT products while 500 ng was used for detecting 2-
LTR circles and integrated provirus. As previously described
(Yap et al., 2006), primer pairs HIVEF/HIVER and 2LTRF/
2LTRR were used to detect early RT product RU5 and 2-LTR
circles respectively in a 25 μl reaction containing 12.5 μl
Sybergreen mix (Abgene) and 70 nm of each primer. The
reactions were performed in the ABI Prism 7000 sequence
detection system from AB Applied Biosystems, using a
program that consisted of an initial incubation at 50 °C for
2 min followed by 95 °C for 15 min before 40 cycles of 95 °C
for 15 s and 60 °C for 1 min.
Protein purification
The DNA sequence coding for Fv1(1–200)CypAwas cloned
into a pET22b expression vector (Novagen) to produce an N-
terminal hexa-histidine fusion protein. The nucleotide sequence
of the expression clone was verified by automated DNA
sequencing and the protein expressed in E. coli BL21 (DE3) by
addition of 1 mM IPTG to a mid-log culture.
Cells were lysed by sonication and Fv1(1–200)CypA was
purified from clarified crude cell extracts using immobilised
metal ion affinity (Ni-NTA) and gel filtration chromatography
(Superdex 200). The purity of preparations was monitored by
SDS–PAGE and the protein concentration was determined from
the absorbance at 280 nm using a molar extinction coefficient
derived by summing the contributions from tyrosine and
tryptophan residues: Fv1(1–200)CypA, ε280=40,700.
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The solution molecular weight of Fv1(1–200)CypA was
determined using on line multi-angle laser light scattering
coupled with size exclusion chromatography. Samples of Ni
affinity-purified Fv1(1–200)CypA (200 μg) were applied to a
Superdex 200 10/300 GL column equilibrated in 20 mM Tris–
HCl, 150 mM NaCl 1 mM TCEP at a flow rate of 0.5 ml/min.
The column was mounted on a Jasco HPLC controlled by the
Chrompass software package. The Scattered light intensity of
the column eluent was recorded at sixteen angles using a
DAWN–HELEOS multi-angle laser light scattering detector
(Wyatt Technology Corp., Santa Barbara, CA). The Protein
concentration of the eluent was determined from the refractive
index change (dn/dc=0.186) using an OPTILAB–rEX differ-
ential refractometer equipped with a Peltier temperature-
regulated flow cell, maintained at 25 °C (Wyatt Technology
Corp., Santa Barbara, CA). The wavelength of the laser in the
DAWN–HELEOS and the light source in the OPTILAB–rEX
was 658 nm. The weight-averaged molecular weight of material
contained in chromatographic peaks was determined using the
ASTRA software version 5.1 (Wyatt Technology Corp., Santa
Barbara, CA). Briefly, at 1-s intervals throughout the elution of
the Fv1-cyp peak the scattered light intensities together with the
corresponding protein concentration were used to construct
Debye plots (KC/Rθ vs. sin
2(θ/2)). The weight-averaged
molecular weight was then calculated at each point in the
chromatogram from the intercept of an individual plot. An
overall average molecular weight and polydispersity term was
calculated by combining and averaging the data from the
individual measurements.
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